Decheng Capital China Life Sciences USD Fund III, L.P. has demonstrated a clear selling bias in its recent trading activity, exclusively divesting shares of BeyondSpring Inc. (BYSI) across 25 transactions between September 15 and October 17, 2025. The fund has not reported any purchases during this period, aligning with its broader trading history of 63 total transactions—all sales—amounting to over $2.02 million in aggregate value. The disposals varied in size, ranging from smaller transactions like the $1,038 sale on October 2 to more substantial dispositions, including a $147,572.56 transaction on October 16 and an $182,513.70 sale on October 13.
The concentrated selling activity suggests a strategic reduction in the fund's position in BeyondSpring, with the most significant transactions clustered in mid-October. Notably, the fund executed five sales exceeding $47,000 during this period, indicating an acceleration in divestment. While the reasons for the sales remain undisclosed, the pattern reflects a consistent exit from BYSI, the sole company in which the fund has reported transactions. The absence of any buying activity reinforces Decheng Capital's directional shift away from this holding, as evidenced by the uninterrupted stream of Form 4 filings detailing its disposals.
AI-assisted summary